MusclePharm Corporation
MSLPQ
$0.00
$0.000.00%
| 03/31/2022 | 12/31/2021 | ||||
|---|---|---|---|---|---|
| Revenue | 30.46% | -16.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.46% | -16.11% | |||
| Cost of Revenue | 9.68% | -11.50% | |||
| Gross Profit | 386.34% | -1,917.24% | |||
| SG&A Expenses | 14.63% | 0.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.90% | -8.81% | |||
| Operating Income | 38.11% | -16.62% | |||
| Income Before Tax | 7.66% | -74.93% | |||
| Income Tax Expenses | -- | -250.00% | |||
| Earnings from Continuing Operations | 7.01% | -72.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.01% | -72.29% | |||
| EBIT | 38.11% | -16.62% | |||
| EBITDA | 37.73% | -17.06% | |||
| EPS Basic | 5.18% | -68.93% | |||
| Normalized Basic EPS | 17.28% | -95.75% | |||
| EPS Diluted | 8.21% | -72.50% | |||
| Normalized Diluted EPS | 17.28% | -95.75% | |||
| Average Basic Shares Outstanding | -1.95% | 1.98% | |||
| Average Diluted Shares Outstanding | -1.95% | 1.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
